Changes in ovarian cancer survival during the 20 years before the era of targeted therapy

被引:89
作者
Lee, Jung-Yun [1 ]
Kim, Sunghoon [1 ]
Kim, Young Tae [1 ]
Lim, Myong Cheol [2 ,3 ]
Lee, Boram [4 ]
Jung, Kyu-Won [4 ]
Kim, Jae Weon [5 ]
Park, Sang-Yoon [2 ,3 ]
Won, Young-Joo [4 ]
机构
[1] Yonsei Univ, Inst Womens Life Med Sci, Dept Obstet & Gynecol, Coll Med, Seoul, South Korea
[2] Natl Canc Ctr, Gynecol Canc Branch, Goyang, South Korea
[3] Natl Canc Ctr, Ctr Uterine Canc, Goyang, South Korea
[4] Natl Canc Ctr, Canc Registrat & Stat Branch, Goyang, South Korea
[5] Seoul Natl Univ, Dept Obstet & Gynecol, Coll Med, Seoul, South Korea
关键词
Ovarian cancer; Survival; Histology; Korea; Chemotherapy; Surgery; PHASE-III TRIAL; GYNECOLOGIC-ONCOLOGY-GROUP; CLEAR-CELL CARCINOMA; EPITHELIAL OVARIAN; STAGE-III; OPEN-LABEL; BEVACIZUMAB; PACLITAXEL; CISPLATIN; CHEMOTHERAPY;
D O I
10.1186/s12885-018-4498-z
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The survival of patients with ovarian cancer has improved because of surgery and chemotherapy. This study aimed to estimate the changes in survival rates among Korean women with ovarian cancer prior to the introduction of targeted therapy for ovarian cancer. Methods: Data were obtained from the Korea Central Cancer Registry regarding patients who were diagnosed with epithelial ovarian cancer between 1995 and 2014. The relative survival rates were calculated for 5-year periods using the Ederer II method. Cox proportional hazard models were created to assess the associations of demographic and clinicopathological factors with ovarian cancer survival. Results: During the study period, 22,880 women were diagnosed with epithelial ovarian cancer. The 5-year relative survival rate improved from 57.2% during 1995-1999 to 63.8% during 2010-2014 (P < 0.001). Survival outcomes improved between 1995 and 1999 and 2010-2014 for the serous and endometrioid carcinoma subtypes (P < 0.001). However, no improvements were observed for the mucinous and clear cell carcinoma subtypes (P = 0.189 and P = 0.293, respectively). Multivariate analysis revealed that younger age, early stage, recent diagnosis, primary surgical treatment, and non-serous histological subtype were favorable prognostic factors. Conclusion: Survival outcomes have improved for serous and endometrioid epithelial ovarian cancer in the last 20 years. However, no improvement was observed for patients with mucinous and clear cell carcinoma subtypes.
引用
收藏
页数:8
相关论文
共 36 条
[1]   OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer [J].
Aghajanian, Carol ;
Blank, Stephanie V. ;
Goff, Barbara A. ;
Judson, Patricia L. ;
Teneriello, Michael G. ;
Husain, Amreen ;
Sovak, Mika A. ;
Yi, Jing ;
Nycum, Lawrence R. .
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (17) :2039-2045
[2]  
[Anonymous], 1994, INT STAT CLASS DIS R
[3]   Intraperitoneal cisplatin and paclitaxel in ovarian cancer [J].
Armstrong, DK ;
Bundy, B ;
Wenzel, L ;
Huang, HQ ;
Baergen, R ;
Lele, S ;
Copeland, LJ ;
Walker, JL ;
Burger, RA .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (01) :34-43
[4]   Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: A meta-analysis [J].
Bristow, RE ;
Tomacruz, RS ;
Armstrong, DK ;
Trimble, EL ;
Montz, FJ .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (05) :1248-1259
[5]   Impact of National Cancer Institute Comprehensive Cancer Centers on Ovarian Cancer Treatment and Survival [J].
Bristow, Robert E. ;
Chang, Jenny ;
Ziogas, Argyrios ;
Campos, Belinda ;
Chavez, Leo R. ;
Anton-Culver, Hoda .
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2015, 220 (05) :940-950
[6]   Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer [J].
Burger, Robert A. ;
Brady, Mark F. ;
Bookman, Michael A. ;
Fleming, Gini F. ;
Monk, Bradley J. ;
Huang, Helen ;
Mannel, Robert S. ;
Homesley, Howard D. ;
Fowler, Jeffrey ;
Greer, Benjamin E. ;
Boente, Matthew ;
Birrer, Michael J. ;
Liang, Sharon X. .
NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (26) :2473-2483
[7]   Patterns and progress in ovarian cancer over 14 years [J].
Chan, John K. ;
Cheung, Michael K. ;
Husain, Amreen ;
Teng, Nelson N. ;
West, Dee ;
Whittemore, Alice S. ;
Berek, Jonathan S. ;
Osann, Kathryn .
OBSTETRICS AND GYNECOLOGY, 2006, 108 (03) :521-528
[8]   Impact of Complete Cytoreduction Leaving No Gross Residual Disease Associated with Radical Cytoreductive Surgical Procedures on Survival in Advanced Ovarian Cancer [J].
Chang, Suk-Joon ;
Bristow, Robert E. ;
Ryu, Hee-Sug .
ANNALS OF SURGICAL ONCOLOGY, 2012, 19 (13) :4059-4067
[9]   A cost-utility analysis of NRG Oncology/Gynecologic Oncology Group Protocol 218: Incorporating prospectively collected quality-of-life scores in an economic model of treatment of ovarian cancer [J].
Cohn, David E. ;
Barnett, Jason C. ;
Wenzel, Lari ;
Monk, Bradley J. ;
Burger, Robert A. ;
Straughn, J. Michael, Jr. ;
Myers, Evan R. ;
Havrilesky, Laura J. .
GYNECOLOGIC ONCOLOGY, 2015, 136 (02) :293-299
[10]   Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial [J].
Coleman, Robert L. ;
Brady, Mark F. ;
Herzog, Thomas J. ;
Sabbatini, Paul ;
Armstrong, Deborah K. ;
Walker, Joan L. ;
Kim, Byoung-Gie ;
Fujiwara, Keiichi ;
Tewari, Krishnansu S. ;
O'Malley, David M. ;
Davidson, Susan A. ;
Rubin, Stephen C. ;
DiSilvestro, Paul ;
Basen-Engquist, Karen ;
Huang, Helen ;
Chan, John K. ;
Spirtos, Nick M. ;
Ashfaq, Raheela ;
Mannel, Robert S. .
LANCET ONCOLOGY, 2017, 18 (06) :779-791